DH DHR Danaher Corporation Loading... : Bullish and Bearish Analyst Opinions

Abbott's continuous glucose monitoring (CGM) growth is slowing in percentage terms but maintaining a billion-dollar annual increase, with management citing SGLT2 crossover (only 1 million out of 6 million users on CGM) as a significant untapped market expansion opportunity. — This highlights a major growth segment for CGM that competitors like Dexcom (DXCM) and Medtronic (MDT) are also chasing, but Abbott's dominant market position and new dual-glucose ketone sensor could give it a decisive edge.